Jean-Paul Kress
At a Glance
Date of birth
August 01, 1965
Nationality
French
First elected or appointed
January 2025
Term expires
General Meeting 2026
Education and Business Experience
Jean-Paul Kress, M.D., is Chief Executive Officer and Chairman of the Board of Vor Bio, a US listed company. Vor Bio is a clinical-stage biotechnology company specialized in the treatment of autoimmune diseases.
Prior to this, Jean-Paul Kress served as the CEO of MorphoSys from 2019 until it was acquired by Novartis in 2024. He has also been the CEO of Syntimmune, where he sharpened the company’s focus on late-stage clinical development in auto-immune diseases until the company’s acquisition by Alexion and has held several senior leadership roles at other pharmaceutical companies in the US and in Europe. Jean-Paul Kress served as Chairman of the Board of Directors at ERYTECH Pharma and was a member of Sarepta Therapeutics’ Board of Directors.
He received his M.D. from Faculté Necker-Enfants Malades in Paris and Master of Sciences in molecular and cellular pharmacology from Ecole normale supérieure (Ulm) in Paris.
Directorships & Appointments
Inside the Sanofi Group
Independent director
Member of the Strategy Committee
Member of the Scientific Committee
Outside the Sanofi Group*
Vor Bio: Chief Executive Officer and Chairman of the Board
Meet the Sanofi Board of Directors
Frédéric Oudéa
Chairman of the Board of Directors
